A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment

Sponsor

University of Alberta (Other)

Overall Status

Completed

CT.gov ID

NCT02240459

Collaborator

Pfizer (Industry)

Enrollment

Location

Arms

Duration (Months)

1.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to assess the effects of fesoterodine at 4mg and 8mg doses versus a placebo and oxybutynin 5mg bid versus placebo on cognitive abilities in older people with overactive bladder and mild cognitive impairment.

Condition or Disease	Intervention/Treatment	Phase
Overactive Bladder Mild Cognitive Impairment	Drug: fesoterodine 4mg Drug: Oxybutynin Drug: placebo Drug: fesoterodine 8mg	Phase 2

Detailed Description

This is a randomized placebo controlled, blinded four way cross over trial of the effect of medications used to treat overactive bladder on the cognition of older men and women with mild cognitive impairment. Each treatment phase is a week, with a weeks washout period before starting the next treatment. Cognitive testing is by way of a validated computer assisted battery of tests

Study Design

Study Type:

Interventional

Actual Enrollment :

47 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Other

Official Title:

A Double Blind, Randomized Four Way Cross Over Study to Compare the Effect of Fesoterodine 4mg and 8mg Once Daily and Oxybutynin 5mg Twice Daily After Steady State Dosing Versus Placebo on Cognitive Function in Subjects With Overactive Bladder, Over the Age of 75 Years With Mild Cognitive Impairment

Study Start Date :

Aug 1, 2016

Actual Primary Completion Date :

Jan 31, 2020

Actual Study Completion Date :

Jan 31, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Fesoterodine 4mg daily fesoterodine 4mg oral	Drug: fesoterodine 4mg 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning Other Names: Toviaz Drug: Oxybutynin 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo Other Names: ditropan Drug: placebo placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes Other Names: placebo capsule Drug: fesoterodine 8mg 2, 4mg fesoterodine capsules taken together in the morning Other Names: Toviaz 8mg
Experimental: Fesoterodine 8mg Fesoterodine 8mg in form of 2, 4mg tablets	Drug: fesoterodine 4mg 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning Other Names: Toviaz Drug: Oxybutynin 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo Other Names: ditropan Drug: placebo placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes Other Names: placebo capsule Drug: fesoterodine 8mg 2, 4mg fesoterodine capsules taken together in the morning Other Names: Toviaz 8mg
Active Comparator: oxybutynin oxybutynin immediate release, encapsulated 2, 5mg capsules daily	Drug: fesoterodine 4mg 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning Other Names: Toviaz Drug: Oxybutynin 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo Other Names: ditropan Drug: placebo placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes Other Names: placebo capsule Drug: fesoterodine 8mg 2, 4mg fesoterodine capsules taken together in the morning Other Names: Toviaz 8mg
Placebo Comparator: placebo capsule placebo capsule, 2 per day	Drug: fesoterodine 4mg 7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning Other Names: Toviaz Drug: Oxybutynin 5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo Other Names: ditropan Drug: placebo placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes Other Names: placebo capsule Drug: fesoterodine 8mg 2, 4mg fesoterodine capsules taken together in the morning Other Names: Toviaz 8mg

Outcome Measures

Primary Outcome Measures

continuity of attention [1 and 4h post dose]
Continuity of Attention: Accuracy of responding in Choice Reaction Time task Percent Target Detection in Digit Vigilance task False Alarms in Digit Vigilance task

Secondary Outcome Measures

cognitive function [1 and 4h post last dose of study drug]
includes the following domains of cognition power of attention, quality of working memory, quality of episodic secondary memory, speed of memory Montreal Cognitive assessment score

Eligibility Criteria

Criteria

Ages Eligible for Study:

75 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

The subject is either male or female and ≥ 75 years of age.
The subject has OAB as determined by ICS criteria
The subject has mild cognitive impairment as determined by NIA criteria
The subject is competent to give informed consent and perform the tasks associated with the study
The subject has a body mass index (BMI) between 18.0 to 30.0 kg/m2 inclusive.
Written informed consent has been obtained.
The subject is available to complete the study.
At training visits (visit 2): the subject has performed at or above the minimum level on at least one occasion for each individual task measure in cognitive function test training.

Exclusion Criteria:

The subject does not have OAB.
The subject has either dementia or moderate to severe cognitive impairment at screening.
The subject has probable clinical depression as determined by Geriatric Depression Scale (GDS) short form >5 at screening.
Subjects taking any cognitive enhancers (cholinesterase inhibitors or memantine).
The subject has a history of allergy to the study drug(s), to any component of the dosage form or any other allergy, which, in the opinion of the Investigator, contraindicates their participation.
The subject has any clinically significant abnormal heart rate or blood pressure measurements, at the screening visit, which, in the opinion of the Investigator, prevent safe participation in the study. (dBP< 60mmHg or > 90mmHg, sBP < 95mmHg or > 160mmHg or HR < 40bpm or > 100bpm).
Subjects with known history of urinary retention, severe gastrointestinal obstruction (including paralytic ileus or intestinal atony) or severe gastrointestinal conditions (including toxic megacolon or ulcerative colitis), myasthenia gravis, uncontrolled narrow angle glaucoma or shallow interior chamber or subjects deemed to be at risk for these conditions.
Subjects undergoing haemodialysis or who have severe renal impairment.
Subjects with severe hepatic impairment, defined as Child-Pugh grade IV.
Subjects taking potent CYP 3A4 inhibitors which would, under normal circumstances, require adjustment of the dose of the test drugs.
Subject has taken prescribed medication within 14 days prior to the first study day or over-the-counter medicine (including vitamins and herbal remedies) within 48 hours prior to the first study day, which in the opinion of the Investigator, will interfere with the study procedures or compromise safety.
Subject has an average weekly alcohol intake of greater than 21 units (male) or 14 units (female) within the 90 days prior to the study. 1 unit is 270cc of beer, 40cc of spirits or 125cc of wine.
History of smoking more than 10 cigarettes (or the equivalent amount of tobacco) per day within the 90 days prior to the study.
Subject has participated in any clinical study within the last 90 days.
Any clinically significant abnormality following Investigator review of the pre study physical examination.
Any clinical condition, which, in the opinion of the Investigator, would not allow safe completion of the study.
Any subjects who, in the opinion of the investigator, may find it difficult to adhere to the provisions of treatment and observation specified in the protocol.